Imsidolimab(抗IL-36受体单抗)治疗泛发性脓疱型银屑病:II期GALLOP试验结果
GALLOP是一项开放标签、单臂、多剂量II期研究,评估抗IL-36受体抗体imsidolimab治疗泛发性脓疱型银屑病(GPP)的疗效与安全性。8例患者接受静脉750mg后三次皮下100mg,主要终点为第4周和第16周临床反应比例。结果显示症状和脓疱快速持续消退,总体耐受良好,无死亡,已推进至III期试验。
要点
- imsidolimab治疗GPP在多项疗效评估中显示快速且持续的改善,最早第3天即可观察到反应。
- 大多数治疗中出现的不良事件为轻至中度,2例患者发生严重不良事件,无死亡报告。
- 研究为开放标签单臂设计,8例入组6例完成,结果支持靶向IL-36信号通路作为GPP治疗选择。
核心结论
- Imsidolimab在GPP患者中表现出症状和脓疱性皮疹的快速且持续消退,总体耐受良好,安全性可接受,正推进至III期试验。
- 这些数据支持将特异性抗体imsidolimab靶向IL-36信号通路作为这一严重致衰弱疾病的治疗选择。
研究设计与样本
- 开放标签、单臂、多剂量研究,评估imsidolimab治疗GPP患者的临床疗效、耐受性和安全性。
- 患者第1天接受imsidolimab 750 mg静脉给药,随后在第29、57和85天接受三次imsidolimab 100 mg皮下给药。
- 主要疗效终点为治疗后第4周和第16周达到临床反应的患者比例,采用临床总体印象量表评估。
- 共入组8例患者,6例完成研究。
主要发现
- 反应最早在第3天即可观察到,脓疱相对于GPP其他表现改善最为迅速,并在第8天、第29天至第113天的多项疗效评估中持续一致改善。
- 大多数治疗中出现的不良事件(TEAE)为轻至中度;没有患者因非严重TEAE而中断研究。
- 2例患者发生严重不良事件(SAE);无死亡报告。
关键数值与推荐
- 主要疗效终点为第4周和第16周临床反应比例,采用临床总体印象量表评估。
- 给药方案:第1天静脉imsidolimab 750 mg,第29、57、85天皮下imsidolimab 100 mg。
临床怎么用
- 原文结论指出imsidolimab表现出快速且持续的症状和脓疱性皮疹消退,总体耐受良好,安全性可接受,正推进至III期试验。
- 原文认为这些数据支持靶向IL-36信号通路(特异性抗体imsidolimab)作为这一严重致衰弱疾病的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalized pustular psoriasis (GPP) is a systemic inflammatory disease that can be severe, debilitating and life threatening. Uncontrolled activation of interleukin (IL)-36 proinflammatory activity may underlie the pathogenesis of GPP. Currently, GPP-specific treatment options are limited. OBJECTIVES: To evaluate the efficacy and safety of the anti-IL-36 receptor antibody imsidolimab in patients with GPP. METHODS: In an open-label, single-arm, multiple-dose study, patients with GPP were treated with imsidolimab to assess clinical efficacy, tolerability and safety. Patients received an intravenous dose of imsidolimab 750 mg on day 1, followed by three subcutaneous doses of imsidolimab 100 mg administered on days 29, 57 and 85. The primary efficacy endpoint was the proportion of patients who achieved a clinical response at weeks 4 and 16 following treatment with imsidolimab, as measured by the Clinical Global Impression scale. RESULTS: Eight patients were enrolled and six completed the study. Responses were observed as early as day 3, most rapidly for pustulation relative to other manifestations of GPP, with continued and consistent improvement across multiple efficacy assessments at day 8, day 29 and through day 113. Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity. No patient discontinued the study owing to a nonserious TEAE. Two patients experienced serious adverse events (SAEs); no deaths were reported. CONCLUSIONS: Imsidolimab demonstrated a rapid and sustained resolution of symptoms and pustular eruptions in patients with GPP. It was generally well tolerated, with an acceptable safety profile, and is advancing to phase III trials. These data support the targeting of IL-36 signalling with a specific antibody - imsidolimab - as a therapeutic option for this severely debilitating condition.
引用
- Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023. PMID: 37120722. doi:10.1093/bjd/ljad083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。